Gillmore Staging (ATTR Amyloidosis) Calculator
- Gillmore Staging (ATTR Amyloidosis): Explanation and Clinical Context
Gillmore staging is a validated system to stratify prognosis in patients with transthyretin (ATTR) cardiac amyloidosis, using serum NT-proBNP and renal function (eGFR) as key predictors.
Stage 1 corresponds to NT-proBNP < 3000 ng/L and eGFR > 45 mL/min/1.73m², indicating the lowest risk group.
Stage 2 includes patients who meet only one of the above criteria (either NT-proBNP > 3000 ng/L or eGFR < 45 mL/min/1.73m²), representing intermediate risk.
Stage 3 applies to patients with both NT-proBNP > 3000 ng/L and eGFR < 45 mL/min/1.73m², representing the highest risk group.
This tool helps clinicians with risk stratification, management decisions, and prognostication for ATTR cardiac amyloidosis.
Reference:
Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39(30):2799–2806. doi:10.1093/eurheartj/ehy219
QUALITY & SAFETY
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.
Please describe the issue clearly. For calculation concerns, include the input values and expected result where possible.